Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Impact of BRAFV600E Mutation on Event Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population

Adela Nechifor-Boila
* ORCID logo ,
Ancuta Cota
,
Claudia Banescu
,
Valeriu Moldovan
,
Doina Piciu
ORCID logo ,
Septimiu Voidazan
,
Angela Borda
Version 1 : Received: 5 July 2023 / Approved: 6 July 2023 / Online: 6 July 2023 (07:14:21 CEST)

A peer-reviewed article of this Preprint also exists.

Nechifor-Boilă, A.; Zahan, A.; Bănescu, C.; Moldovan, V.; Piciu, D.; Voidăzan, S.; Borda, A. Impact of BRAFV600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population. Cancers 2023, 15, 4053. Nechifor-Boilă, A.; Zahan, A.; Bănescu, C.; Moldovan, V.; Piciu, D.; Voidăzan, S.; Borda, A. Impact of BRAFV600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population. Cancers 2023, 15, 4053.

Abstract

We aimed to assess the prognostic value of BRAFV600E mutation in a series of 127 papillary thyroid carcinoma (PTC) cases as a single factor, as well as in synergic interaction with other standard risk factors. All cases were tested for BRAFV600E mutation by real-time PCR. Event-free survival (EFS) was calculated between the date of the first evaluation and the date of occurrence of an adverse event (tumor recurrence/distant metastasis) or the date of the last known status. The prevalence of BRAFV600E mutation was 57.2%. The Kaplan-Meyer analysis showed a significant reduction of EFS among cases harboring BRAFV600E mutation compared to non-mutated cases (p=0.010). In addition, BRAFV600E mutation was found to better predict adverse outcomes when associated with the following risk factors: age≥55 years-old (p<0.001), male gender (p<0.001), conventional (p=0.005) and tall cell (p=0.014) histology, tumor size&gt;40mm (p=0.001), extrathyroidal extension (p=0.001), multifocality (p=0.001) and lymph node metastasis (p&lt;0.001). In univariate analysis, a 3.74-fold increased risk for a reduced EFS (p=0.018) was found for BRAFV600E mutated cases. Our results highlight the prognostic value of BRAFV600E mutation in PTCs. Moreover, the synergic interaction between BRAFV600E mutation and other risk factors seems more valuable in terms of prognosis, compared to BRAFV600E mutation alone.

Keywords

papillary thyroid cancer; BRAFV600E mutation; lymph node metastasis; prognosis; outcomes.

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.